The Electrophoresis Market size in the Asia Pacific is estimated to be growing at a CAGR of 6.72% between 2022 to 2027. This market is estimated to be worth USD 0.53 billion by 2027 from USD 0.38 billion in 2022.
The growing use of next-generation sequencing (NGS), research-based academic and pharmaceutical industry collaborations and increased diagnostic application are driving the growth of the APAC electrophoresis market. As a result, the use of electrophoretic techniques in clinical diagnostic testing is growing rapidly, such as hemoglobin testing, enzymes (ALP, LDH, and CK), plasma, serum, urine, cerebrospinal fluid, multiple myeloma testing, lipoprotein, and hormone measurements, among others. In addition, with use in the evaluation of protein expression profiles and disease-specific biomarkers for disease identification contributes to the market's rapid growth.
Due to the difference in charge between the mixtures, various complex biological molecules, such as antibiotics, vitamins, and proteins, can be effectively separated by electrophoresis. This technique is widely adopted due to its lower price and ease of performance. The International Olympic Committee also uses the electrophoresis reaction to conduct drug tests among players to help detect illegal supplements taken by athletes to improve their performance and blood alcohol levels. Unfortunately, almost 80% of deaths in China among 60-year-old are due to chronic non-communicable diseases. Some of the most common chronic diseases seen in the APAC region are ischemic heart disease, type 2 diabetes, stroke, chronic obstructive pulmonary disease.
Electrophoresis is also used in the preparation of antibiotics and to test the resistance of pathogens, purification, and analysis of different types of vaccines such as hepatitis and influenza, genetic analysis, and formation of personalized medicine. Furthermore, with the constant ongoing research and development in medicine and pharmaceutical, emerging markets' growth provides significant growth opportunities for market players throughout the forecast period.
Despite technological advancements in the process, electrophoresis heavily depends on the machines that record and analyze the data. This use of any electrophoresis system, as electrophoresis is limited to one room with an external power supply, is a challenge for the market growth. Furthermore, the risk of contamination and technique sensitivity may also restraint the market. In addition, the slowness of operation and the availability of alternative technologies are hampering the market's growth.
This research report segmented and sub-segmented the APAC Electrophoresis Market into the following categories:
By End Users:
In 2020, the market in China had dominated the APAC electrophoresis market mainly due to the sudden increase in diagnostics, clinical trials, and vaccine development for the COVID-19 pandemic. In addition, the growing attention in this regional market can be attributed to the advantage of low-cost manufacturing, which also provides growth opportunities for manufacturers. Furthermore, the fast-growing pharmaceutical industries in emerging economies are expected to attract international commercial investments to grow the market in the region.
The major players in this market have focused on the emerging economies of the APAC region, focusing on expansions and acquisitions to gain a more significant market share in the coming years. In addition, there is a growing demand for personalized medicine, and the emphasis on proteomics research is creating opportunities in the other APAC regional markets such as Korea, Australia, Singapore, and Japan.
The electrophoresis market in India is expected to grow at a significant CAGR of 8.1% due to the increased public and private investment in R&D, improving healthcare infrastructure, high incidence of chronic disease, and growing demand for medical tourism. In addition, per India's foreign direct investment policy, a 175,000 square foot bio-incubator space has been planned in India to support 50 world-class bio-incubators by 2020. According to the India Brand Equity Foundation (IBEF) report, the Indian government is expected to invest approximately US $ 3.7 billion in the biotechnology sector during the twelfth five-year plan. This is anticipated to provide sound market growth opportunities for the Electrophoresis market in India.
KEY MARKET PLAYERS:
Companies playing a dominating role in the Asia Pacific electrophoresis market profiled in the report are Bio-Rad Laboratories, GE Healthcare, Thermo Fisher Scientific Inc, Danaher Corporation, Agilent Technologies, Merck Millipore, PerkinElmer, QIAGEN N.V., Lonza Group Ltd., Shimadzu Corporation, Harvard Bioscience, Sebia Group, and C.B.S. Scientific Company.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]